studies

squamous cell - mNSCLC - L1, anti-PD-(L)1 vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMpower-131 (ACnP), 2020 0.88 [0.73; 1.06] KEYNOTE-407, 2018 0.64 [0.49; 0.84] 0.76[0.56; 1.04]IMpower-131 (ACnP), 2020, KEYNOTE-407, 2018273%1,242moderatenot evaluable progression or deaths (PFS)detailed resultsIMpower-131 (ACnP), 2020 0.71 [0.60; 0.85] KEYNOTE-407, 2018 0.56 [0.45; 0.70] 0.64[0.51; 0.80]IMpower-131 (ACnP), 2020, KEYNOTE-407, 2018263%1,242moderatenot evaluable DORdetailed resultsIMpower-131 (ACnP), 2020 2.14 [1.13; 4.04] 2.14[1.13; 4.04]IMpower-131 (ACnP), 202010%309NAnot evaluable objective responses (ORR)detailed resultsIMpower-131 (ACnP), 2020 1.42 [1.05; 1.92] KEYNOTE-407, 2018 2.20 [1.57; 3.09] 1.76[1.14; 2.70]IMpower-131 (ACnP), 2020, KEYNOTE-407, 2018272%1,242moderatenot evaluable AE (any grade)detailed resultsIMpower-131 (ACnP), 2020 5.12 [1.11; 23.56] KEYNOTE-407, 2018 1.20 [0.36; 3.96] 2.29[0.55; 9.43]IMpower-131 (ACnP), 2020, KEYNOTE-407, 2018254%1,226lownot evaluable AE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.37 [0.98; 1.90] KEYNOTE-407, 2018 0.99 [0.70; 1.39] 1.17[0.85; 1.60]IMpower-131 (ACnP), 2020, KEYNOTE-407, 2018244%1,226moderatenot evaluable AE leading to death (grade 5)detailed resultsIMpower-131 (ACnP), 2020 2.59 [1.36; 4.92] KEYNOTE-407, 2018 1.31 [0.69; 2.49] 1.84[0.95; 3.59]IMpower-131 (ACnP), 2020, KEYNOTE-407, 2018254%1,226lownot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMpower-131 (ACnP), 2020 2.09 [1.45; 3.02] KEYNOTE-407, 2018 2.28 [1.45; 3.61] 2.17[1.63; 2.88]IMpower-131 (ACnP), 2020, KEYNOTE-407, 201820%1,226moderatenot evaluable AE leading to treatment discontinuation (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.09 [1.28; 3.39] 2.09[1.28; 3.39]KEYNOTE-407, 201810%558NAnot evaluable SAE (any grade)detailed resultsIMpower-131 (ACnP), 2020 2.28 [1.66; 3.14] 2.28[1.66; 3.14]IMpower-131 (ACnP), 202010%668NAnot evaluable STRAE (any grade)detailed resultsIMpower-131 (ACnP), 2020 2.27 [1.46; 3.51] 2.27[1.46; 3.51]IMpower-131 (ACnP), 202010%668NAnot evaluable TRAE (any grade)detailed resultsIMpower-131 (ACnP), 2020 1.80 [0.98; 3.28] 1.80[0.98; 3.28]IMpower-131 (ACnP), 202010%668NAnot evaluable TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.57 [1.14; 2.15] 1.57[1.14; 2.15]IMpower-131 (ACnP), 202010%668NAnot evaluable TRAE leading to death (grade 5)detailed resultsIMpower-131 (ACnP), 2020 1.34 [0.30; 6.02] KEYNOTE-407, 2018 1.70 [0.61; 4.75] 1.58[0.68; 3.68]IMpower-131 (ACnP), 2020, KEYNOTE-407, 201820%1,226lownot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 2.00 [0.07; 59.91] 2.00[0.07; 59.91]IMpower-131 (ACnP), 202010%668NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 1.00[0.02; 50.55]IMpower-131 (ACnP), 202010%668NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.09 [0.76; 1.58] 1.09[0.76; 1.58]IMpower-131 (ACnP), 202010%668NAnot evaluable Arthralgia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 1.00[0.02; 50.55]IMpower-131 (ACnP), 202010%668NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 0.77 [0.28; 2.10] 0.77[0.28; 2.10]IMpower-131 (ACnP), 202010%668NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 8.08 [0.43; 153.53] 8.08[0.43; 153.53]IMpower-131 (ACnP), 202010%668NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 0.50 [0.02; 14.93] 0.50[0.02; 14.93]IMpower-131 (ACnP), 202010%668NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 3.41 [0.93; 12.49] 3.41[0.93; 12.49]IMpower-131 (ACnP), 202010%668NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 6.05 [0.30; 121.16] 6.05[0.30; 121.16]IMpower-131 (ACnP), 202010%668NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.44 [0.54; 3.83] 1.44[0.54; 3.83]IMpower-131 (ACnP), 202010%668NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.89 [0.75; 4.80] 1.89[0.75; 4.80]IMpower-131 (ACnP), 202010%668NAnot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 2.66 [1.10; 6.46] 2.66[1.10; 6.46]IMpower-131 (ACnP), 202010%668NAnot evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 1.00[0.02; 50.55]IMpower-131 (ACnP), 202010%668NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.06; 16.05] 1.00[0.06; 16.05]IMpower-131 (ACnP), 202010%668NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 2.00 [0.07; 59.91] 2.00[0.07; 59.91]IMpower-131 (ACnP), 202010%668NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 4.02 [0.18; 89.44] 4.02[0.18; 89.44]IMpower-131 (ACnP), 202010%668NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 1.00[0.02; 50.55]IMpower-131 (ACnP), 202010%668NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.46 [0.72; 2.93] 1.46[0.72; 2.93]IMpower-131 (ACnP), 202010%668NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 1.00[0.02; 50.55]IMpower-131 (ACnP), 202010%668NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 1.00[0.02; 50.55]IMpower-131 (ACnP), 202010%668NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 3.55 [0.73; 17.23] 3.55[0.73; 17.23]IMpower-131 (ACnP), 202010%668NAnot evaluable Nephritis TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 1.00[0.02; 50.55]IMpower-131 (ACnP), 202010%668NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 0.93 [0.65; 1.35] 0.93[0.65; 1.35]IMpower-131 (ACnP), 202010%668NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 2.00 [0.07; 59.91] 2.00[0.07; 59.91]IMpower-131 (ACnP), 202010%668NAnot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 2.01 [0.37; 11.06] 2.01[0.37; 11.06]IMpower-131 (ACnP), 202010%668NAnot evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 4.04 [0.45; 36.31] 4.04[0.45; 36.31]IMpower-131 (ACnP), 202010%668NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.68 [0.40; 7.07] 1.68[0.40; 7.07]IMpower-131 (ACnP), 202010%668NAnot evaluable Rash TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 2.01 [0.18; 22.23] 2.01[0.18; 22.23]IMpower-131 (ACnP), 202010%668NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 1.00[0.02; 50.55]IMpower-131 (ACnP), 202010%668NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.16 [0.68; 2.00] 1.16[0.68; 2.00]IMpower-131 (ACnP), 202010%668NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 3.02 [0.31; 29.16] 3.02[0.31; 29.16]IMpower-131 (ACnP), 202010%668NAnot evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 10.24 [0.56; 188.30] 10.24[0.56; 188.30]KEYNOTE-407, 201810%558NAnot evaluable Alopecia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.33 [0.03; 3.22] 0.33[0.03; 3.22]KEYNOTE-407, 201810%558NAnot evaluable Anaemia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.72 [0.46; 1.11] 0.72[0.46; 1.11]KEYNOTE-407, 201810%558NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.03 [0.37; 11.17] 2.03[0.37; 11.17]KEYNOTE-407, 201810%558NAnot evaluable Asthenia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.60 [0.21; 1.66] 0.60[0.21; 1.66]KEYNOTE-407, 201810%558NAnot evaluable Colitis AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.04 [0.50; 8.23] 2.04[0.50; 8.23]KEYNOTE-407, 201810%558NAnot evaluable Constipation AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.67 [0.11; 4.04] 0.67[0.11; 4.04]KEYNOTE-407, 201810%558NAnot evaluable Cough AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.67 [0.11; 4.04] 0.67[0.11; 4.04]KEYNOTE-407, 201810%558NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 1.21 [0.37; 4.02] 1.21[0.37; 4.02]KEYNOTE-407, 201810%558NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 1.88 [0.69; 5.16] 1.88[0.69; 5.16]KEYNOTE-407, 201810%558NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 3.04 [0.31; 29.44] 3.04[0.31; 29.44]KEYNOTE-407, 201810%558NAnot evaluable Epistaxis AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 1.01 [0.02; 50.94] 1.01[0.02; 50.94]KEYNOTE-407, 201810%558NAnot evaluable Fatigue AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.82 [0.33; 2.01] 0.82[0.33; 2.01]KEYNOTE-407, 201810%558NAnot evaluable Hyperthyroidism AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.02 [0.07; 60.40] 2.02[0.07; 60.40]KEYNOTE-407, 201810%558NAnot evaluable Hypophysitis AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 4.05 [0.18; 90.23] 4.05[0.18; 90.23]KEYNOTE-407, 201810%558NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.02 [0.07; 60.40] 2.02[0.07; 60.40]KEYNOTE-407, 201810%558NAnot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 4.07 [0.45; 36.67] 4.07[0.45; 36.67]KEYNOTE-407, 201810%558NAnot evaluable Myalgia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.02 [0.18; 22.43] 2.02[0.18; 22.43]KEYNOTE-407, 201810%558NAnot evaluable Nausea AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.75 [0.17; 3.39] 0.75[0.17; 3.39]KEYNOTE-407, 201810%558NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.90 [0.61; 1.32] 0.90[0.61; 1.32]KEYNOTE-407, 201810%558NAnot evaluable Peripheral neuropathy AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 1.52 [0.25; 9.15] 1.52[0.25; 9.15]KEYNOTE-407, 201810%558NAnot evaluable Pneumonitis AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 3.07 [0.61; 15.32] 3.07[0.61; 15.32]KEYNOTE-407, 201810%558NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 1.01 [0.14; 7.20] 1.01[0.14; 7.20]KEYNOTE-407, 201810%558NAnot evaluable Severe skin reactions AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 3.04 [0.31; 29.44] 3.04[0.31; 29.44]KEYNOTE-407, 201810%558NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 1.07 [0.55; 2.08] 1.07[0.55; 2.08]KEYNOTE-407, 201810%558NAnot evaluable Thyroiditis AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.02 [0.07; 60.40] 2.02[0.07; 60.40]KEYNOTE-407, 201810%558NAnot evaluable Vomiting AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.16 [0.02; 1.38] 0.16[0.02; 1.38]KEYNOTE-407, 201810%558NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:13 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 308,164,166,220 - treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563